Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  

Marstacimab

Kishanlal Munshi: EC Approves Pfizer’s HYMPAVZI for Hemophilia A and B With Inhibitors
May 17, 2026, 18:42 | Voices
Kishanlal Munshi: EC Approves Pfizer’s HYMPAVZI for Hemophilia A and B With Inhibitors
Kishanlal Munshi, Vice President-Technical at Sarabhai Group, shared a post on LinkedIn: "European Commission Approves…
Wolfgang Miesbach: Rebalancing Agents in Haemophilia Are Not “Set and Forget” - Key Insights from WFH 2026
Apr 21, 2026, 14:26 | Voices
Wolfgang Miesbach: Rebalancing Agents in Haemophilia Are Not “Set and Forget” - Key Insights from WFH 2026
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared posts on LinkedIn, highlighting key…
Wolfgang Miesbach: The Most Underappreciated Challenges in Haemophilia Care Tackled at WFH 2026
Apr 20, 2026, 15:03 | Voices
Wolfgang Miesbach: The Most Underappreciated Challenges in Haemophilia Care Tackled at WFH 2026
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn: ''WFH…
Wolfgang Miesbach: The Benefit with Hemophilia Rebalancing Agents Is Real, But So Are The Open Questions
Mar 27, 2026, 17:15 | Voices
Wolfgang Miesbach: The Benefit with Hemophilia Rebalancing Agents Is Real, But So Are The Open Questions
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn about a recent article…
Wolfgang Miesbach: A Remarkable Progress With Non-Factor Therapies in Hemophilia Care
Mar 26, 2026, 15:19 | Insight
Wolfgang Miesbach: A Remarkable Progress With Non-Factor Therapies in Hemophilia Care
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn: ''Non-factor therapies in…
Wolfgang Miesbach: Targeted Anti-TFPI Therapy with Marstacimab Supports Joint Stability in Hemophilia A
Mar 6, 2026, 12:02 | Insight
Wolfgang Miesbach: Targeted Anti-TFPI Therapy with Marstacimab Supports Joint Stability in Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn: ''Michael…
Wolfgang Miesbach: Efficacy, Safety and Thrombosis Signals in Haemophilia A/B with Inhibitors
Feb 25, 2026, 15:09 | Voices
Wolfgang Miesbach: Efficacy, Safety and Thrombosis Signals in Haemophilia A/B with Inhibitors
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn: ''Efficacy, safety…
Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
Jan 16, 2026, 04:11 | Insight
Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn: "Safety Signal:…
Stroke-Associated Letal Outcome with Hympavzi: Michael Makris on Pfizer's Announcement
Dec 23, 2025, 05:14 | Drugs
Stroke-Associated Letal Outcome with Hympavzi: Michael Makris on Pfizer's Announcement
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of…
Wolfgang Miesbach Shares Insights from Davide Matino's Presentation on Marstacimab at ASH25
Dec 15, 2025, 11:28 | Insight
Wolfgang Miesbach Shares Insights from Davide Matino's Presentation on Marstacimab at ASH25
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn: ''ASH25: Introducing fixed-dose…
Marstacimab Shows 93% Reduction in Treated Bleeds in its Phase 3 Trial
Sep 11, 2025, 13:37 | Drugs
Marstacimab Shows 93% Reduction in Treated Bleeds in its Phase 3 Trial
National Bleeding Disorders Foundation shared on LinkedIn: ''Promising news for the hemophilia community! Pfizer’s HYMPAVZI™…
Insights from Michael Makris: FAERS Reveals Thrombotic Events for Marstacimab
Sep 3, 2025, 03:05 | Drugs
Insights from Michael Makris: FAERS Reveals Thrombotic Events for Marstacimab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief…
Michael Makris Shares French Regulatory Update: Marstacimab (Hympavzi) Not Recommended for Severe Haemophilia A or B
Aug 30, 2025, 14:39 | Insight
Michael Makris Shares French Regulatory Update: Marstacimab (Hympavzi) Not Recommended for Severe Haemophilia A or B
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief…
Beyond Factor Therapy: Marstacimab for Hemophilia Care
Aug 21, 2025, 14:49 | Insight
Beyond Factor Therapy: Marstacimab for Hemophilia Care
World Federation of Hemophilia (WFH) shared a post on X: "Beyond factor therapy: Marstacimab targets…
Encouraging Phase 3 Results: Marstacimab for Hemophilia A or B with Inhibitors
Jul 19, 2025, 20:01 | Drugs
Encouraging Phase 3 Results: Marstacimab for Hemophilia A or B with Inhibitors
Heme Today shared a thrilled post on LinkedIn: ''ICYMI in hemophilia reporting on Heme Today: Marstacimab…
All: 15 Posts: 1 - 100
NewsFeed